Characterization of rVSVΔG-ZEBOV-GP glycoproteins using automated capillary western blotting. Issue 45 (21st October 2020)

• Record Type: Journal Article
• Authors: Minsker, Kevin; Rustandi, Richard R.; Ha, Sha; Loughney, John W.
• Is Part Of: Vaccine. Volume 38:Issue 45(2020)
• Page Start: 7166
• Page End: 7174
• Publication Date: 2020-10-21
• Subjects: Capillary western blotting -- Ebola -- ERVEBO® -- Glycoprotein -- Vaccine -- rVSVΔG-ZEBOV-GP; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.08.001
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Capillary western blotting is used to characterize glycoproteins in ERVEBO®, an approved Ebola vaccine. Understanding of glycoprotein structure variants present within ERVEBO® product. Data show high ratio of membrane-bound GP to soluble GP. Abstract: Ebolavirus (EBOV) entry to host cells requires membrane-associated glycoprotein (GP). A recombinant vesicular stomatitis virus vector carrying Zaire Ebola virus glycoprotein (rVSV-ZEBOV) was developed as a vaccine against ebolaviruses. The VSV glycoprotein gene was deleted (rVSVΔG) and ZEBOV glycoprotein (GP) was inserted into the deleted VSV glycoprotein open reading frame (ORF) resulting in a live, replication-competent vector (rVSVΔG-ZEBOV-GP). Automated capillary westerns were used to characterize the rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) manufacturing process with regards to glycoprotein (GP) structure and variants. The method shows a unique electropherogram profile for each process step which could be used to monitor process robustness. rVSVΔG-ZEBOV-GP encodes GP (GP1-GP2), secreted GP (sGP), and small secreted GP (ssGP) variants. Furthermore, a TACE-like activity was observed indirectly by detecting soluble GP2Δ after virus precipitation by ultracentrifugation. Capillary western blotting techniques can guide process development by evaluating process steps such as enzyme treatment. In addition, the technique can assess GP stability and process lot-to-lot consistency. Finally, capillary western-based technology was used to identify a unique biochemical profile of the rVSVΔG-ZEBOV-GP vaccine strain in final product. Virion membrane-bound GP1-GP2 is critical to vaccine-elicited protection by providing both neutralizing antibodies and T-cell response.